Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257267 | 1.00 | GBA1 (0.51) | GBA1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL2403331 | 1.00 | GBA1 (0.51) | GBA1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL6468540 | 0.93 | HSD17B10 (0.48) | GBA1KMT2AMAPTHSD17B10LMNA | |
| SCHEMBL1257628 | 0.93 | HSD17B10 (0.48) | GBA1KMT2AMAPTHSD17B10LMNA | |
| SCHEMBL1256185 | 0.91 | HSD17B10 (0.44) | GBA1MEN1KMT2AMAPTHSD17B10 | |
| SCHEMBL6372167 | 0.91 | GBA1 (0.58) | GBA1MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL1257258 | 0.91 | GBA1 (0.58) | GBA1MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL6371868 | 0.91 | GBA1 (0.58) | GBA1MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL1258594 | 0.89 | HSD17B10 (0.42) | GBA1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL1257439 | 0.89 | HSD17B10 (0.42) | GBA1MEN1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8648197-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880002-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237601-A1 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CCR2 | GBA1 2527/4885MEN1 3404/4885ALDH1A1 2286/4885 |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CCR2 | GBA1 2527/4885MEN1 3404/4885ALDH1A1 2286/4885 |
| US-20130123270-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CCR2 | GBA1 2527/4885MEN1 3404/4885ALDH1A1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.